1. The DOPPS Practice Monitor for US Dialysis Care: Update on Trends in Anemia Management 2 Years Into the Bundle 
Douglas S. Fuller, MS, Ronald L. Pisoni, PhD, MS, Brian A. Bieber, MPH, MS, Friedrich K. Port, MD, MS, Bruce M. Robinson, MD, MS 
American Journal of Kidney Diseases 
Volume 62, Issue 6, Pages (December 2013)
DOI: /j.ajkd
Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Hemoglobin (Hb) level distribution in the DPM national sample from August 2010 to December Based on 1,744 to 3,838 patients per month among facilities providing laboratory records for at least 10 patients.
Adapted with permission of Arbor Research Collaborative for Health from the April 2013 update to the DOPPS Practice Monitor.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions

3. Figure 2
Change in facility mean hemoglobin (Hb) concentrations and mean weekly intravenous (IV) epoetin dose from August 2010 to August Based on 53 and 44 facilities providing laboratory records for at least 10 patients in August 2010 and August 2012.
Adapted with permission of Arbor Research Collaborative for Health from the April 2013 update to the DOPPS Practice Monitor.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions

4. Figure 3
Facility variation in selected hemoglobin (Hb) measures, December Based on 77 facilities providing laboratory records for at least 10 patients. ∗“ESA-treated” includes patients prescribed any erythropoiesis-stimulating agent (ESA) between October and December 2012.
Adapted with permission of Arbor Research Collaborative for Health from the April 2013 update to the DOPPS Practice Monitor.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions

5. Figure 4
Distribution of prescribed weekly intravenous (IV) epoetin dose, August 2010 to December Values for each month reflect the average IV epoetin dose prescribed to patients during 1 week of each study month (restricted to 1, ,000U/mo) in facilities providing renal medication records for at least 10 patients.
Adapted with permission of Arbor Research Collaborative for Health from the April 2013 update to the DOPPS Practice Monitor.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions

6. Figure 5
Facility variation in selected anemia measures, December Prescribed intravenous (IV) epoetin dose, based on 72 facilities; values reflect average weekly dose prescribed (restricted to 1, ,000U/mo). IV iron use, based on 78 facilities; values reflect any prescription during prior month. Ferritin and transferrin saturation (TSAT), based on 82 (ferritin) and 81 (TSAT) facilities; values reflect the most recent measurement obtained within the prior 3 months. Data based on only facilities providing renal medication (IV epoetin dose, IV iron use) or laboratory data (ferritin, TSAT) for at least 10 patients.
Adapted with permission of Arbor Research Collaborative for Health from the April 2013 update to the DOPPS Practice Monitor.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions